Kurv Yield Premium Strategy Tesla TSLA ETF(TSLP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TSLP Kurv Yield Premium Strategy Tesla TSLA ETF

Post-Mkt 12-15 17:34:08 EST

25.23

+0.69

+2.81%

盘后24.80

-0.43-1.70%

16:50 EST

High25.37	Low24.63	Vol17.67K
Open24.63	D1 Closing24.54	Amplitude3.01%
Mkt Cap23.46M	Tradable Cap23.46M	Total Shares930.00K
T/O445.41K	T/O Rate1.90%	Tradable Shares930.00K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TSLP","market":"US","secType":"STK","nameCN":"Kurv Yield Premium Strategy Tesla TSLA ETF","latestPrice":25.23,"timestamp":1765832400000,"preClose":24.5399,"halted":0,"volume":17673,"hourTrading":{"tag":"盘后","latestPrice":24.8,"preClose":25.23,"latestTime":"16:50 EST","volume":29,"amount":723.499975,"timestamp":1765835414907},"delay":0,"floatShares":930000,"shares":930000,"eps":0,"marketStatus":"Post-Mkt","change":0.6901,"latestTime":"12-15 17:34:08 EST","open":24.63,"high":25.3695,"low":24.63,"amount":445405.620492,"amplitude":0.030135,"askPrice":26.22,"askSize":4,"bidPrice":21.38,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1765846800000},"marketStatusCode":4,"adr":0,"exchange":"AMEX","adjPreClose":24.5399,"sharesOutstanding":930000,"nav":23.89,"aum":22217700,"dividendRate":0.346849,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":24.8,"preClose":25.23,"latestTime":"16:50 EST","volume":29,"amount":723.499975,"timestamp":1765835414907},"volumeRatio":1.340733,"impliedVol":0.4169,"impliedVolPercentile":0.744},"requestUrl":"/m/hq/s/TSLP/tweets","defaultTab":"tweets","newsList":[{"id":"2588213877","title":"Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma Engineered with AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2588213877","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588213877?lang=en_us&edition=fundamental","pubTime":"2025-12-01 19:00","pubTimestamp":1764586800,"startTime":"0","endTime":"0","summary":"SOLAIRIA-1 and SOLAIRIA-2 will evaluate GB-0895 in approximately 1,600 patients with severe asthma whose disease remains inadequately controlled on current therapies. GB-0895 is an antibody optimized using AI to achieve ultra-high-affinity TSLP binding, extended half-life, and high specificity. It is being developed as a long-acting therapy designed for dosing every six months to help reduce the treatment burden for people with severe asthma. GB-0895 is also being evaluated in a Phase 1 clinical trial in chronic obstructive pulmonary disease .Phase 1 Results Presented at ERS 2025Dave Singh, MD, professor of clinical pharmacology and respiratory medicine at the University of Manchester and medical director at the Medicines Evaluation Unit, presented Phase 1 data for GB-0895 at the European Respiratory Society  International Congress 2025 in Amsterdam. In this study of 96 people with mild to moderate asthma, GB-0895 was generally well tolerated across a wide dose range , demonstrated dos","market":"hk","thumbnail":"https://mma.prnewswire.com/media/2594219/generate_bio_logo_rgb_black__3_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2594219/generate_bio_logo_rgb_black__3_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/generatebiomedicines-to-initiate-global-phase-3-studies-of-gb-0895-a-long-acting-anti-tslp-antibody-for-severe-asthma-engineered-with-ai-302628300.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSLP"],"gpt_icon":0},{"id":"2586420640","title":"Upstream Bio to Participate in Upcoming December Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2586420640","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586420640?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:00","pubTimestamp":1764072000,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Nov.  25, 2025  (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respirat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/25/3194193/0/en/Upstream-Bio-to-Participate-in-Upcoming-December-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSLP"],"gpt_icon":0},{"id":"2582852875","title":"Press Release: Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2582852875","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582852875?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:10","pubTimestamp":1762776600,"startTime":"0","endTime":"0","summary":"Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD anticipated in Q1 2026, APEX 16-week Part B data in AD in Q2 2026, and APG279 Phase 1b head-to-head readout against DUPIXENT in AD in 2H 2026. Interim Phase 1 results of APG333 in healthy volunteers reported today exceeded trial objectives, demonstrated a half-life of approximately 55 days, and suppressed key biomarkers for 6 months following a single dose, supporting potential 3- and 6-month dosing and the development of a quarterly or less frequently dosed co-formulation of APG273  for respiratory indications. Completed $345 million public offering; $913 million cash, cash equivalents and marketable securities pro forma as of September 30 supports runway into 2H 2028. Phase 1b data in asthma, AD data from APEX 52-week Part A anticipated in. -- At this year's European Academy of Dermatology a","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2065732104.USD","APGE","PRGS","BK4097","TSLP"],"gpt_icon":0},{"id":"1160394698","title":"CSTONE PHARMA-B (02616): ACAAI 2025 | CS2015 (OX40L/TSLP Bispecific Antibody) Makes International Academic Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=1160394698","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160394698?lang=en_us&edition=fundamental","pubTime":"2025-11-07 08:14","pubTimestamp":1762474478,"startTime":"0","endTime":"0","summary":"CSTONE PHARMA-B (02616) announced that the company will present its autoimmune and inflammation pipeline candidate CS2015 (OX40L/TSLP bispecific antibody) at the 2025 American College of Allergy,...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","TSLP","02616","BK1161"],"gpt_icon":0},{"id":"2581072224","title":"Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2581072224","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581072224?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:00","pubTimestamp":1762344000,"startTime":"0","endTime":"0","summary":"– Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically significant and clinically meaningful effects on primary and key secondary endp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/05/3181264/0/en/Upstream-Bio-Reports-Third-Quarter-2025-Financial-Results-and-Highlights-Continued-Progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4585","XLV","XBI","BK4588","LABU","TSLP","PRGS","BK4097","LU2065732104.USD"],"gpt_icon":0},{"id":"1105079913","title":"HK Stock Movement | KEYMED BIO-B (02162) Rises Over 3% Against Market Trend as CM512 Phase I Trial for Atopic Dermatitis Meets All Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=1105079913","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105079913?lang=en_us&edition=fundamental","pubTime":"2025-11-05 10:08","pubTimestamp":1762308495,"startTime":"0","endTime":"0","summary":"KEYMED BIO-B (02162) surged over 3% against the broader market trend, reaching HK$64.25 with a trading volume of HK$49.02 million by press time. The company announced on November 4 that its...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162","TSLP","BK1574","BK1583","BK1587","BK1161"],"gpt_icon":0},{"id":"2579747468","title":"Upstream Bio to Participate in Upcoming November Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2579747468","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579747468?lang=en_us&edition=fundamental","pubTime":"2025-10-31 19:00","pubTimestamp":1761908400,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Oct.  31, 2025  (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respirat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/31/3178219/0/en/Upstream-Bio-to-Participate-in-Upcoming-November-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSLP"],"gpt_icon":0},{"id":"2571345035","title":"Upstream Bio’s verekitug shows prevention of TSLP binding in respiratory disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2571345035","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571345035?lang=en_us&edition=fundamental","pubTime":"2025-09-30 18:15","pubTimestamp":1759227319,"startTime":"0","endTime":"0","summary":"Upstream Bio (UPB) presented structural and mechanistic data showing verekitug’s potent pharmacodynamic activity through its approach of targeting ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/upstream-bios-verekitug-shows-prevention-of-tslp-binding-in-respiratory-disease-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/upstream-bios-verekitug-shows-prevention-of-tslp-binding-in-respiratory-disease-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","UPB","TSLP"],"gpt_icon":0},{"id":"2571314944","title":"Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug’s Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2571314944","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571314944?lang=en_us&edition=fundamental","pubTime":"2025-09-30 16:15","pubTimestamp":1759220100,"startTime":"0","endTime":"0","summary":"– Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites – – Additionally, findings show that verekitug outcompetes TSLP in the presence of preformed heterodi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/30/3158333/0/en/Upstream-Bio-Presents-Data-Showing-Structural-and-Mechanistic-Drivers-of-Verekitug-s-Potent-Pharmacodynamic-Activity-and-Differentiated-Clinical-Profile-at-European-Respiratory-Soc.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSLP"],"gpt_icon":0},{"id":"1110018463","title":"Sanofi SA (SNY.US) Initiates Phase II/III Clinical Trials for TSLP/IL-13 Dual Antibody in COPD Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1110018463","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110018463?lang=en_us&edition=fundamental","pubTime":"2025-09-26 09:20","pubTimestamp":1758849628,"startTime":"0","endTime":"0","summary":"On September 24, global clinical trial registry data revealed that Sanofi SA (SNY.US) has advanced its TSLP/IL-13 dual antibody Lunsekimig (SAR443765) to Phase II/III development, launching two Phase...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["III","TSLP","BK4007","IE00BFXG1179.USD","SNY","BK4585","BK4588","BK4134"],"gpt_icon":0},{"id":"1115952695","title":"CSTONE PHARMA-B (02616) to Present CS2015 (OX40L/TSLP Bispecific Antibody) at ACAAI 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1115952695","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115952695?lang=en_us&edition=fundamental","pubTime":"2025-09-15 08:04","pubTimestamp":1757894656,"startTime":"0","endTime":"0","summary":"CSTONE PHARMA-B (02616) announced that CS2015, an OX40L/TSLP bispecific antibody from the company's autoimmune and inflammatory disease pipeline, has been selected for presentation at the 2025 Annual...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616","TSLP","BK1574","BK1161"],"gpt_icon":0},{"id":"2566699176","title":"Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2566699176","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566699176?lang=en_us&edition=fundamental","pubTime":"2025-09-09 19:00","pubTimestamp":1757415600,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Sept.  09, 2025  (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respira","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/09/3146737/0/en/Upstream-Bio-to-Participate-in-the-Stifel-2025-Virtual-Immunology-and-Inflammation-Forum.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FET","SF","BK4179","BK4127","TSLP"],"gpt_icon":0},{"id":"2564847995","title":"Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2564847995","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564847995?lang=en_us&edition=fundamental","pubTime":"2025-09-02 05:00","pubTimestamp":1756760400,"startTime":"0","endTime":"0","summary":"Director, Corporate Communications and Investor Relations","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/01/3142285/0/en/Upstream-Bio-to-Host-Conference-Call-and-Webcast-to-Report-Top-Line-Data-from-the-Phase-2-VIBRANT-Trial-of-Verekitug-in-Patients-with-Chronic-Rhinosinusitis-with-Nasal-Polyps-CRSwN.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","HST","TSLP","BK4218","BK4588","BK4181"],"gpt_icon":0},{"id":"1193571556","title":"SINO BIOPHARM (01177) to Present Research Results on \"TQC3721 (PDE3/4 Inhibitor)\", \"TQC2731 (TSLP Monoclonal Antibody)\", and \"TQC3403 (Umeclidinium Bromide Vilanterol Dry Powder Inhaler)\" at ERS 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1193571556","media":"Stock News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193571556?lang=en_us&edition=fundamental","pubTime":"2025-08-25 18:44","pubTimestamp":1756118670,"startTime":"0","endTime":"0","summary":"SINO BIOPHARM (01177) announced that the company's developed \"TQC3721 (PDE3/4 inhibitor)\", \"TQC2731 (TSLP monoclonal antibody)\", and \"TQC3403 (umeclidinium bromide vilanterol dry powder inhaler)\"...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YR35.GBP","BK1589","01177","BK1515","TSLP","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","BK1521","BK1191"],"gpt_icon":0},{"id":"2558547986","title":"Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2558547986","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558547986?lang=en_us&edition=fundamental","pubTime":"2025-08-11 19:00","pubTimestamp":1754910000,"startTime":"0","endTime":"0","summary":"Positive 16-week data from APEX Phase 2 Part A met all primary and key secondary endpoints for APG777, a potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis APEX Par","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/11/3130763/0/en/Apogee-Therapeutics-Provides-Pipeline-Progress-and-Reports-Second-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APGE","BK4139","BK4218","EASI","TSLP","BK4181","LU2065732104.USD","PRGS","BK4097","PK"],"gpt_icon":0},{"id":"2557844379","title":"Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2557844379","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557844379?lang=en_us&edition=fundamental","pubTime":"2025-08-06 19:00","pubTimestamp":1754478000,"startTime":"0","endTime":"0","summary":"– On track to report top-line data from Phase 2 trial in chronic rhinosinusitis with nasal polyps (CRSwNP) in the third quarter of 2025 – – Completed enrollment in Phase 2 trial in severe asthma in Ju","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/06/3128192/0/en/Upstream-Bio-Reports-Second-Quarter-2025-Financial-Results-and-Highlights-Continued-Progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065732104.USD","BK4097","PRGS","TSLP"],"gpt_icon":0},{"id":"2549549905","title":"Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2549549905","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549549905?lang=en_us&edition=fundamental","pubTime":"2025-07-08 19:00","pubTimestamp":1751972400,"startTime":"0","endTime":"0","summary":"– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for vere","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/08/3111591/0/en/Upstream-Bio-Announces-First-Patient-Dosed-in-Phase-2-Clinical-Trial-of-Verekitug-in-Chronic-Obstructive-Pulmonary-Disease-COPD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSLP"],"gpt_icon":1}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0153},{"period":"1month","weight":0.0304},{"period":"3month","weight":0.1361},{"period":"6month","weight":0.1866},{"period":"1year","weight":-0.2275},{"period":"ytd","weight":-0.1893}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"The fund is an actively managed exchange traded fund that seeks current income while maintaining the opportunity for exposure to the share price (i.e., the price returns) of the common stock of Tesla Inc. (“TSLA”); however the strategy limits potential investment gains related to share price appreciation. The fund seeks to employ its investment strategy as it relates to TSLA in all market, economic, or other conditions. The fund is non-diversified.","exchange":"AMEX","name":"Kurv Yield Premium Strategy Tesla TSLA ETF","nameEN":"Kurv Yield Premium Strategy Tesla TSLA ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kurv Yield Premium Strategy Tesla TSLA ETF(TSLP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Kurv Yield Premium Strategy Tesla TSLA ETF(TSLP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Kurv Yield Premium Strategy Tesla TSLA ETF,TSLP,Kurv Yield Premium Strategy Tesla TSLA ETF股票,Kurv Yield Premium Strategy Tesla TSLA ETF股票老虎,Kurv Yield Premium Strategy Tesla TSLA ETF股票老虎国际,Kurv Yield Premium Strategy Tesla TSLA ETF行情,Kurv Yield Premium Strategy Tesla TSLA ETF股票行情,Kurv Yield Premium Strategy Tesla TSLA ETF股价,Kurv Yield Premium Strategy Tesla TSLA ETF股市,Kurv Yield Premium Strategy Tesla TSLA ETF股票价格,Kurv Yield Premium Strategy Tesla TSLA ETF股票交易,Kurv Yield Premium Strategy Tesla TSLA ETF股票购买,Kurv Yield Premium Strategy Tesla TSLA ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kurv Yield Premium Strategy Tesla TSLA ETF(TSLP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Kurv Yield Premium Strategy Tesla TSLA ETF(TSLP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction